BioMarin Pharmaceutical Inc. filed a current report with the SEC on September 1, 2026, disclosing that it completed its acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a wholly owned subsidiary.

Key Highlights

  • Acquisition closed: BioMarin completed the Share Purchase of Alesta Therapeutics B.V. on August 31, 2026.
  • Wholly owned subsidiary: As a result of the transaction, Alesta is now a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
  • Structure: The transaction was completed as a share purchase under a Share Purchase Agreement.
  • Counterparties: The Purchase Agreement involved Alesta, its shareholders, Anaheim SpinCo B.V., and Shareholder Representative Services LLC acting as representative for the Company Participating Equityholders.
  • Prior disclosure: BioMarin had previously announced the Purchase Agreement in a current report filed with the SEC on August 18, 2026.
  • Signing authority: The report was signed by G. Eric Davis, Executive Vice President and Chief Legal Officer of BioMarin.

BioMarin Finalizes Alesta Therapeutics Share Purchase Transaction

According to the filing, BioMarin Pharmaceutical Inc., a Delaware corporation listed on the Nasdaq Global Select Market under the ticker NASDAQ:BMRN, completed its acquisition of Alesta Therapeutics B.V. on August 31, 2026. Alesta is described in the filing as a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid). The transaction was structured as a share purchase, with Alesta's shares acquired directly from the identified holders listed in Schedule 1.1(a) of the Purchase Agreement.

The filing notes that a third Dutch entity, Anaheim SpinCo B.V., was also a party to the Purchase Agreement, alongside Shareholder Representative Services LLC, which acted "solely in its capacity as the representative and attorney-in-fact of the Company Participating Equityholders" as defined in the Purchase Agreement. BioMarin, a biopharmaceutical company headquartered at 770 Lindaro Street, San Rafael, California, had entered into the Purchase Agreement as previously reported in a current report filed with the SEC on August 18, 2026, which included the full text of the Purchase Agreement as Exhibit 2.1.

The filing states that the description of the Purchase Agreement and related transactions "does not purport to be complete and is subject to, and qualified in its entirety by, the text of the Purchase Agreement," with the terms of that earlier exhibit incorporated by reference into this report.

What Was Disclosed

BioMarin Pharmaceutical Inc. disclosed the completion of its share purchase acquisition of Alesta Therapeutics B.V. on August 31, 2026, confirming Alesta's status as a wholly owned subsidiary and referencing the Purchase Agreement filed on August 18, 2026.